Vericel (VCEL) Capital Expenditures Growth (5y) (2015 - 2026)
Vericel (VCEL) Capital Expenditures Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn |
| 10 | Vericel | 2.30 Bn | 2.16 Bn | 49.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.85% |
| Dec 31, 2025 | 89.34% |
| Sep 30, 2025 | -126.29% |
| Jun 30, 2025 | 76.94% |
| Mar 31, 2025 | 81.73% |
| Dec 31, 2024 | -79.79% |
| Sep 30, 2024 | 79.87% |
| Jun 30, 2024 | 79.84% |
| Mar 31, 2024 | 120.58% |
| Dec 31, 2023 | 51.36% |
| Sep 30, 2023 | 2.14% |
| Jun 30, 2023 | 29.61% |
| Mar 31, 2023 | 50.34% |
| Dec 31, 2022 | 59.20% |
| Dec 31, 2020 | 117.36% |
| Sep 30, 2020 | 20.90% |
| Dec 31, 2019 | -34.85% |
| Jun 30, 2018 | 104.92% |
| Mar 31, 2018 | 59.19% |
| Dec 31, 2017 | 47.17% |